tiprankstipranks
NewsSmart PortfolioMarkets
Research Tools
Research Tools
Top Stocks
Top Smart Score Stocks
New
Analysts' Top StocksInsiders' Hot Stocks
Popular
Trending Stocks
Daily Feeds
Daily Stock RatingsDaily Insider Transactions
Screeners
Stock Screener
New
Stock Comparison
New
Smart Portfolio
Smart Portfolio
My Portfolio
OverviewMy HoldingsMy Portfolio AnalysisCrowd Insights
My Community
My PerformanceMy Public Profile
New
Top Experts
Top Experts
Find & Follow Experts
My ExpertsExpert CenterTop Firms
Top Lists
Top 25 Wall Street AnalystsTop 25 Financial BloggersTop 25 Corporate InsidersTop 25 Hedge Fund ManagersTop Individual Investors
New
News
News
Categories
HomeMarket NewsTipRanks LabsIdeas & InsightsStock Analysis
Trending Topics
Coronavirus StocksDividend StocksPenny StocksFAANG Stocks
Calendars
Calendars
Calendars & Events
Earnings CalendarsDividend CalendarsStock Market HolidaysIPO Calendar
Plans & Pricing
NewsSmart PortfolioMarketsNotifications
All News

BIIB

Topic
Biogen’s 4Q Earnings Miss Street Estimates; Shares Fall 5.2%
Biogen’s shares dropped 5.2% on Feb. 3 as the biotech company’s fourth-quarter earnings fell short of analysts’ estimates....
Shrilekha Pethe
BIIB
Biogen Shares Gain 5.5% As FDA Extends Review Period For Alzheimer’s Drug
Biogen shares were up by 5.5% on Jan. 29 after the pharma company announced that the U.S. Food...
Shrilekha Pethe
BIIB
Gilead Sciences or Biogen: Which Biotech Stock is a Better Pick for 2021?
An unprecedented pandemic did not stop the US stock market from finishing 2020 on a high note. The...
Sirisha Bhogaraju
BIIBGILD
Sage Therapeutics Gets $1.53B From Biogen in a Collaboration Deal
Sage Therapeutics received $1.525 billion from Biogen under the earlier announced collaboration and license agreement to jointly develop...
Amit Singh
BIIBSAGE
Biogen Files For Japan Approval Of Potential Alzheimer Treatment; Street Says Hold
Biogen has filed a new drug application to Japan’s regulator for the approval of aducanumab, its investigational treatment...
Sharon Wrobel
BIIB
Biogen Bombs at the FDA Panel; J.P. Morgan Weighs In
By a vote of one for, eight against, and two abstaining, the U.S. Food and Drug Administration’s (FDA)...
TipRanks Team
IBBBIIB
Biogen Rockets 44% On “Substantial Evidence” For Alzheimer’s Drug Approval
Shares of Biogen exploded 44% after staff at the US Food and Drug Administration (FDA) concluded in a...
Sharon Wrobel
BIIB
Biogen’s Tecfidera Now Faces Cipla Generic Launch; Analyst Wary
Global pharma Cipla has announced that it has received final approval for its generic therapeutic equivalent version of...
Harriet Lefton
BIIB
AbbVie vs Biogen: Which Drugmaker Scores A ‘Strong Buy’ Street Consensus?
The COVID-19 pandemic has led to a wake-up call for governments, as they realize the significant investment required...
Sirisha Bhogaraju
ABBVBIIB
Biogen Spikes 10% On FDA Fast Review For Potential Alzheimer Treatment
Shares in Biogen leaped 10% on Friday after the company said that the U.S. Food and Drug Administration...
Sharon Wrobel
BIIB
Biogen Rises 4% As Morgan Stanley Upgrades Stock To Buy
Shares in Biogen (BIIB) rose over 4% in early-market trading on Monday, after Morgan Stanley lifted the stock’s rating...
Amit Singh
BIIB
Biogen, Eisai Start New Phase 3 Trial For Pre-clinical Alzheimer’s Disease
Biogen (BIIB), in collaboration with Eisai, and the Alzheimer’s Clinical Trials Consortium, has initiated a new global Phase...
Harriet Lefton
BIIB
Biogen: Approval Prospects for Aducanumab Amount to a Flip of a Coin, Says J.P. Morgan
Not all biotechs are highflyers in 2020. Despite some pharma companies’ elevated coronavirus driven valuations, some have had...
Marty Shtrubel
BIIB
Biogen Files FDA Application For Potential Alzheimer Treatment 
Biogen Inc. (BIIB) announced that it has finally submitted the Biologics License Application (BLA) seeking approval by the...
Sharon Wrobel
BIIB